Miravitlles, MarcAlcazar, BernardinoAlvarez, Francisco JavierBazus, TeresaCalle, MyriamCasanova, CiroCisneros, Carolinade-Torres, Juan P.Entrenas, Luis M.Esteban, CristobalGarcia-Sidro, PatriciaGarcía-Cosío, BorjaHuerta, ArturoIriberri, MilagrosIzquierdo, Jose LuisLopez-Vina, AntolnLopez-Campos, Jose LuisMartinez-Moragon, EvaPerez de Llano, Luis AlejandroPerpina, MiguelRos, Jose AntonioSerrano Pariente, JoséSoler-Cataluna, Juan JoseTorrego, AlfonsUrrutia, IsabelPlaza, Vicente2024-07-042024-07-042015Miravitlles M, Alcazar B, Javier Alvarez F, Bazus T, Calle M, Casanova C, et al. What pulmonologists think about the asthma-COPD overlap syndrome. Int J Chronic Obstr Pulm Dis. 2015;10:1321-30.1178-2005http://hdl.handle.net/20.500.13003/17190http://hdl.handle.net/20.500.12105/20089Background: Some patients with COPD may share characteristics of asthma; this is the so-called asthma-COPD overlap syndrome (ACOS). There are no universally accepted criteria for ACOS, and most treatments for asthma and COPD have not been adequately tested in this population. Materials and methods: We performed a survey among pulmonology specialists in asthma and COPD aimed at collecting their opinions about ACOS and their attitudes in regard to some case scenarios of ACOS patients. The participants answered a structured questionnaire and attended a face-to-face meeting with the Metaplan methodology to discuss different aspects of ACOS. Results: A total of 26 pulmonologists with a mean age of 49.7 years participated in the survey (13 specialists in asthma and 13 in COPD). Among these, 84.6% recognized the existence of ACOS and stated that a mean of 12.6% of their patients might have this syndrome. In addition, 80.8% agreed that the diagnostic criteria for ACOS are not yet well defined. The most frequently mentioned characteristics of ACOS were a history of asthma (88.5%), significant smoking exposure (73.1%), and postbronchodilator forced expiratory volume in 1 second/forced vital capacity,0.7 (69.2%). The most accepted diagnostic criteria were eosinophilia in sputum (80.8%), a very positive bronchodilator test (69.2%), and a history of asthma before 40 years of age (65.4%). Up to 96.2% agreed that first-line treatment for ACOS was the combination of a long-acting beta(2)-agonist and inhaled steroid, with a long-acting antimuscarinic agent (triple therapy) for severe ACOS. Conclusion: Most Spanish specialists in asthma and COPD agree that ACOS exists, but the diagnostic criteria are not yet well defined. A previous history of asthma, smoking, and not fully reversible airflow limitation are considered the main characteristics of ACOS, with the most accepted first-line treatment being long-acting beta(2)-agonist/inhaled corticosteroids.enghttps://creativecommons.org/licenses/by-nc/3.0/AsthmaCOPDACOSSurveyGuidelinesAsthmaSpainPulmonary MedicineAdrenal Cortex HormonesPulmonary Disease, Chronic ObstructiveHumansSmokingHealth Knowledge, Attitudes, PracticeBronchodilator AgentsMiddle AgedPrognosisAdrenergic beta-2 Receptor AgonistsMalePredictive Value of TestsAnti-Asthmatic AgentsAttitude of Health PersonnelFemaleRisk FactorsConsensusSpecializationresearch articleAttribution-NonCommercial 3.0 Unported26270415101321-133010.2147/COPD.S88667International Journal of Chronic Obstructive Pulmonary Diseaseopen accessEspecializaciónAntiasmáticosFemeninoActitud del Personal de SaludMasculinoConsensoFumarEnfermedad Pulmonar Obstructiva CrónicaFactores de RiesgoBroncodilatadoresHumanosPersona de Mediana EdadValor Predictivo de las PruebasConocimientos, Actitudes y Práctica en SaludPronósticoAsmaEncuestas y CuestionariosCorticoesteroidesAgonistas de Receptores Adrenérgicos beta 2NeumologíaEspaña2-s2.0-84937564455357981500001L605215364